Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 14.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 53,654 shares of the medical equipment provider’s stock after selling 8,849 shares during the quarter. HighTower Advisors LLC’s holdings in Zimmer Biomet were worth $5,667,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the business. Stonebridge Financial Group LLC acquired a new stake in Zimmer Biomet in the 4th quarter valued at approximately $25,000. Dunhill Financial LLC grew its stake in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 218 shares in the last quarter. Brooklyn Investment Group acquired a new position in shares of Zimmer Biomet during the third quarter valued at $35,000. Kentucky Trust Co bought a new stake in shares of Zimmer Biomet during the fourth quarter valued at about $39,000. Finally, OFI Invest Asset Management acquired a new stake in Zimmer Biomet in the fourth quarter worth about $40,000. Institutional investors own 88.89% of the company’s stock.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at $915,379.20. This represents a 14.13 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.95% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ZBH shares. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their target price for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Stifel Nicolaus raised their price objective on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research note on Thursday, January 23rd. Barclays cut their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Royal Bank of Canada lowered their price target on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Finally, Raymond James cut their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $112.91 on Thursday. Zimmer Biomet Holdings, Inc. has a 12 month low of $97.69 and a 12 month high of $133.90. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The stock has a market cap of $22.48 billion, a PE ratio of 25.37, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The business has a fifty day simple moving average of $106.41 and a 200-day simple moving average of $106.93.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the firm posted $2.20 earnings per share. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.85%. Zimmer Biomet’s dividend payout ratio is presently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.